Your kidney mass has been surgically removed and analysed by our pathology department. It has been confirmed as a renal cell carcinoma (kidney cancer).

The stage and grade are as follows. Please see the Macmillan Cancer Support Understanding Kidney Cancer booklet for more information

Stage T1a T1b
T2a T2b
T3a T3b T3c
Grade 1 2 3 4

Based on your pathology results you have been placed on the intermediate risk follow up protocol. Regular follow up is important. It enables us to monitor the remaining kidney and check for any residual or recurrent disease.

You will receive regular follow up appointments, either by telephone or face to face with your consultant or Clinical Nurse Specialist (CNS).

Your follow up will involve blood tests, CT scans and appointments at timely intervals.

We recommend 6 monthly blood tests to check your kidney function. These will need to be done through your GP’s surgery. You can get in touch with your CNS for the results.

Your CT scans should happen at 1 year, 2 years, 3 years, and 5 years from your operation date (unless unavoidable delays).

If you do not receive appointments as outlined in this information sheet by the month in which they are due, please get in touch with your CNS or your consultant’s secretary so that we are aware and able to chase them up.

If you have any questions or concerns at any time between appointments please do get in contact with your CNS or your consultant’s secretary. If your call is not answered, leave a message, with your name and contact number and we will aim to return your call within 72 hours.


Clinical Nurse Specialists

Sophie Davies 0300 422 4336

Karen Edwards 0300 422 6672

Consultant’s secretary

Ms. Davenport 0300 422 3156

Mr. Henderson 0300 422 6902

Miss McMeekin 0300 422 4272

Mr. Nettleton 0300 422 6671

Mr. Okeke 0300 422 6903

Available Monday to Friday, 8:00 am to 4:00 pm

Printable version of this page

Intermediate risk protocol for kidney cancer Department: Urology Review due: June 2025 PDF, 226.2 KB, 2 pages
Reference number GHPI1739_06_22
Department Urology
Review due June 2025